Advancing Treatment of EGFR-Positive Metastatic Non-Small Cell Lung Cancer

home / insights / advancing-treatment-of-egfr-positive-metastatic-non-small-cell-lung-cancer

Cara Chang, PharmD, BCOP, and Alan Chin, PharmD, BCOP, engage in a comprehensive discussion about EGFR mutation therapies, relevant clinical trials, associated adverse reactions, and crucial strategies for optimizing patient outcomes in this specific subset of NSCLC patients.

1 KOL is featured in this program

EP. 1: Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

June 21st 2024

Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.

Watch

1 KOL is featured in this program

EP. 2: Examining Key Data from the FLAURA2 and MIRAPOSA Trials

June 21st 2024

A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.

Watch

© 2024 MJH Life Sciences

All rights reserved.